Follistatin is a protein your body makes on its own. It is not a simple peptide, but a larger protein that helps control growth and repair in the body. Scientists study it in labs, and some people seek versions of it made outside the body. It is not an approved medicine.
Follistatin works by blocking other proteins called activin and myostatin. Myostatin puts the brakes on muscle growth, so blocking it may allow muscles to grow more. Follistatin also plays roles in healing, in the brain where it may support learning and memory, and in women's reproductive health. Because of its effects on muscle, it has drawn interest from people who want to build strength.
Much is still unknown. Almost all the research has been done in animals or lab cells, not in people. In some countries, follistatin has been found in seized black-market doping products, so quality and safety of such products are serious concerns. There is no approved dosing guidance, and risks are not well understood. Anyone considering it should know the science in humans is not settled.
Benefits
The benefits people report — backed by research.
You just read the research on Follistatin. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Evidence
Every claim above traces back to a source you can check — here are 32 of them.
FST follistatin [Homo sapiens (human)] - Gene
FST follistatin [ Homo sapiens (human) ]
Fst follistatin [ Mus musculus (house mouse) ]
Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone.
Human follistatin-related protein: a structural homologue of follistatin with nuclear localization.
Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.
Elevated circulating follistatin associates with an increased risk of type 2 diabetes.
Elevated circulating follistatin associates with increased risk of mortality and cardiometabolic disorders.
The activin-follistatin system: Key regulator of kidney development, regeneration, inflammation, and fibrosis
Identification of follistatin as a possible trait-causing gene in polycystic ovary syndrome.
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.
Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity.
The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.
Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Activin-type II receptor B (ACVR2B) and follistatin haplotype associations with muscle mass and strength in humans.
News
Dated, sourced reporting that mentions Follistatin.
Coverage of the Phase 1/2a trial of AAV-delivered FS344 follistatin gene therapy in Becker muscular dystrophy patients. The majority of patients showed significant gains in six-minute walk distance and stair-climbing tests. Investigator Jerry Mendell called it the first gene therapy clinical trial to demonstrate functional improvement in any form of muscular dystrophy.
The paper reviews the first clinical follistatin gene therapy trial using the FS344 isoform in Becker muscular dystrophy. Six ambulatory BMD patients received dose-ascending AAV-delivered FS344 to build muscle mass. In each cohort of three subjects, two patients improved in the distance walked on the six-minute walk test.
FDA warned Tailor Made Compounding LLC (Nicholasville, KY) after a 2018 inspection found it compounded drug products with bulk substances ineligible for 503A exemptions. The letter explicitly lists the compounded substances: Follistatin, GHRP-2, GHRP-6, AOD 9604, BPC 157, Bremelanotide (PT-141), Cerebrolysin, DSIP, Epitalon, GHK-Cu, Ipamorelin, LL-37, Melanotan II, Selank, Semax, and CJC 1295, among others. The firm was cited for insanitary aseptic processing (adulteration), unapproved new drugs, and misbranding, and removed GHRP-2 and GHRP-6 from its formulary in response.
Wondering how Follistatin pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Explore by goal
Compare
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.